| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CLEC2B |
| Uniprot No | Q92478 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-149aa |
| 氨基酸序列 | MMTKHKKCFIIVGVLITTNIITLIVKLTRDSQSLCPYDWIGFQNKCYYFSKEEGDWNSSKYNCSTQHADLTIIDNIEEMNFLRRYKCSSDHWIGLKMAKNRTGQWVDGATFTKSFGMRGSEGCAYLSDDGAATARCYTERKWICRKRIH |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于 **CLEC2B重组蛋白** 的示例参考文献(内容为虚构示例，实际文献需通过学术数据库检索)：
---
1. **文献名称**：*"Recombinant CLEC2B Protein Enhances NK Cell Activation via Interaction with NKp80"*
**作者**：A. Smith et al.
**摘要**：研究通过大肠杆菌表达系统成功制备了重组CLEC2B蛋白，并证明其与自然杀伤细胞(NK细胞)表面受体NKp80特异性结合，促进NK细胞的细胞毒性活性，揭示了CLEC2B在先天免疫中的潜在调控机制。
2. **文献名称**：*"Structural and Functional Characterization of CLEC2B as a Novel C-Type Lectin Ligand"*
**作者**：L. Chen & H. Wang
**摘要**：通过X射线晶体学解析了CLEC2B重组蛋白的三维结构，发现其具有独特的糖识别域(CRD)，并验证了其与树突状细胞表面糖蛋白的相互作用，为开发基于CLEC2B的免疫疗法提供了结构基础。
3. **文献名称**：*"CLEC2B Recombinant Protein Suppresses Tumor Growth by Modulating T Cell Responses"*
**作者**：K. Tanaka et al.
**摘要**：在小鼠模型中，注射CLEC2B重组蛋白显著抑制了黑色素瘤的生长，机制研究表明其通过激活CD8+ T细胞并增强IFN-γ分泌发挥抗肿瘤作用，提示CLEC2B在癌症免疫治疗中的应用潜力。
---
如需真实文献，建议在 **PubMed** 或 **Google Scholar** 中检索关键词：`CLEC2B recombinant protein`、`CLEC2B function` 或 `CLEC2B immune regulation`。
CLEC2B (C-type lectin domain family 2 member B) is a transmembrane protein belonging to the C-type lectin superfamily, which plays critical roles in immune regulation, cell adhesion, and pathogen recognition. This protein, also known as activation-induced C-type lectin (AICL) or CD69 ligand, is primarily expressed on activated immune cells, including natural killer (NK) cells, T cells, and platelets. Structurally, CLEC2B features a conserved carbohydrate-recognition domain (CRD) that enables calcium-dependent binding to specific glycans, though its exact physiological ligands remain under investigation.
CLEC2B interacts with cell-surface receptors such as NKRP1 (CD161) and possibly CD69. modulating immune cell activation, migration, and cytotoxicity. It has been implicated in inflammatory responses, viral infections (e.g., HIV), and cancer progression. Notably, CLEC2B may regulate platelet aggregation through interactions with podoplanin, a protein expressed on lymphatic endothelial cells and certain tumor cells.
Recombinant CLEC2B protein is produced using expression systems like Escherichia coli or mammalian cells, often fused with tags (e.g., His-tag) for purification and detection. Its applications include studying ligand-receptor interactions, screening therapeutic agents targeting immune disorders or thrombosis, and developing diagnostic tools for diseases linked to CLEC2B dysregulation. Abnormal CLEC2B expression has been observed in hematologic malignancies and chronic inflammation, highlighting its potential as a biomarker or therapeutic target. Ongoing research aims to clarify its signaling mechanisms and therapeutic relevance in immune-mediated diseases and cancer.
×
